

Jubbonti® (denosumab-bbdz) – First-time interchangeable biosimilar launch

- On June 2, 2025, <u>Sandoz launched Jubbonti (denosumab-bbdz)</u>, biosimilar and *interchangeable* to Amgen's Prolia[®] (denosumab).
 - Jubbonti is available at a list price (Wholesale Acquisition Cost [WAC]) 14% below the current Prolia list price (\$1,604.13 per package).
- Jubbonti was FDA-approved in March 2024.
- Additional biosimilars to Prolia have been approved with pending launch dates:
 - Samsung Bioepis' Ospomyv™ (denosumab-dssb)
 - Celltrion's Stoboclo® (denosumab-bmwo)
 - Fresenius Kabi's Conexxence® (denosumab-bnht).
- Jubbonti and Prolia share the following indications:
 - Treatment of postmenopausal women with osteoporosis at high risk for fracture
 - Treatment to increase bone mass in men with osteoporosis at high risk for fracture
 - Treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture
 - Treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
 - Treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.
- Like Prolia, Jubbonti carries a boxed warning for severe hypocalcemia in patients with advanced kidney disease.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.